Journey Medical reports Q3 EPS (12c), consensus (15c)

Reports Q3 revenue $14.63M, consensus $14.39M. Claude Maraoui, Journey Medical’s (DERM) Co-Founder, President and Chief Executive Officer, said, “Given the recent FDA approval of Emrosi(TM), (Minocycline Hydrochloride Extended Release Capsules, 40 mg), formerly referred to as DFD-29, for the treatment of inflammatory lesions of rosacea in adults, we are completing manufacturing activities and deploying our experienced dermatology sales force to quickly enable patient access to this unique therapeutic solution. This approval is a transformational milestone for both Journey Medical and the dermatology community, as Emrosi has the potential to become the best-in-class oral medication and standard of care to address inflammatory lesions of rosacea.”